Effectiveness of ranolazine at admission and/or discharge in reducing re-admissions after PCI
Approximately 1.5 million people undergo diagnostic cardiac catheterization or percutaneous coronary intervention (PCI) every year in the United States. Of these, 9-16% are re-admitted within 30 days, and these patients are at high risk of dying or suffering a heart attack or stroke within 1 year. Ranolazine is a medication currently used to treat angina, but that also has anti-arrhythmic and anti-inflammatory effects. As such, it may prevent some of the complications that develop after cardiac catheterization/PCI, reducing patients’ need to be re-admitted to the hospital and their costs of care.
This population-based, multi-site observational study will provide important information about ranolazine’s potential to prevent short- and long-term re-hospitalizations after cardiac catheterization/PCI, and the associated impact on costs of care. This information will be useful in updating clinical guidelines/best practices for patients undergoing cardiac catheterization/PCI, and to decision-makers setting policies regarding the indications for and re-imbursement coverage of ranolazine as a prophylactic and/or therapeutic agent.
Role: Giovanni Filardo: Principal Investigator, Teresa Phan: Data Coordinator